NCT02253264View on ClinicalTrials.gov

A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Interventions
DRUG

Rituximab

Trial Locations (1)

21287

The Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT02253264 - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter